On June 23, 2026, the Department of Justice (DOJ) announced the 2026 National Health Care Fraud Takedown, resulting in charges against 455 defendants—including 90 doctors and other licensed medical professionals—for alleged participation in health care fraud and opioid abuse schemes involving over $6.5 billion in false claims. The operation spanned 45 states and involved the seizure of more than $182 million in cash, luxury vehicles, jewelry, and other assets.
Coordinated by the DOJ’s Health Care Fraud Strike Force teams, the FBI, Department of Health and Human Services Office of Inspector General, Drug Enforcement Administration (DEA), and Centers for Medicare & Medicaid Services (CMS), this is primarily a criminal enforcement action, though it includes a meaningful civil component and dovetails with the DOJ’s broader civil False Claims Act enforcement push. In particular, it’s clear that CMS will be stepping up its authority to take early action with revocations of billing privileges and suspensions of providers at the first sign of suspected fraud.
The 2026 takedown charged more defendants than the prior year’s action (455 versus 324 in 2025) but a smaller headline dollar figure ($6.5 billion versus $14.6 billion in 2025). The comparison warrants context: the 2025 takedown’s total was heavily inflated by a single transnational criminal organization—Operation Gold Rush—alleged to have submitted over $10 billion in fraudulent claims. This year’s figures, while lower in aggregate, reflect a broader distribution of schemes and defendants and the DOJ’s growing ability to detect fraud early through AI and advanced data analytics to charge a wider range of actors.
Data Analytics as the New Enforcement Engine
The DOJ described the operation as involving the “cutting-edge use of data analytics to target the worst actors.” The Health Care Fraud Unit’s Data Analytics Team detected a spike in payments for amniotic wound allografts (skin substitutes) that led directly to prosecutions. This is unsurprising. The DOJ has been building a Health Care Fraud Data Fusion Center that leverages cloud computing, artificial intelligence, and advanced analytics to detect emerging schemes in near-real time. The use of these tools is leading to faster action at all levels, as we recently forecast in our advisory on the DOJ’s new fast-tracking of benefits fraud qui tams.
This continues a theme practitioners should heed: as Commercial Litigation Branch Deputy Assistant Attorney General Brenna Jenny has warned, “your next whistleblower could be your data.” CMS Administrator Dr. Mehmet Oz echoed this posture, noting that “the numbers tell the story.” Companies whose billing patterns diverge from peer norms or are significant outliers should expect proactive scrutiny—whether or not a qui tam complaint has been filed.
Wound Care and Skin Substitutes: An Emerging Priority
Among the most notable enforcement actions in this year’s takedown are charges filed against 11 defendants—including a company executive and eight medical professionals—in connection with billions of dollars in fraudulent claims for amniotic wound allografts. The alleged kickbacks caused defendants to target hospice patients and apply allografts (without coordination with treating physicians and without proper treatment for infection) to superficial wounds that did not need the treatment and to areas far exceeding the size of the wound—resulting in significant patient harm.
CMS separately reinforced this enforcement priority by reducing Medicare’s reimbursement for skin substitutes to $127 per square centimeter starting January 1, 2026. The combination of criminal prosecution and reimbursement reform signals that wound care fraud is a durable enforcement priority, not a one-off focus.
Perennial Focus Areas: Telemedicine, Genetic Testing, Durable Medical Equipment, and Opioids
The takedown targeted schemes across the full spectrum of health care fraud, including:
- False billing and medically unnecessary services
- Kickback arrangements between providers, laboratories, and marketers
- Telemedicine and genetic testing fraud
- Durable medical equipment (DME) fraud
- Opioid and controlled-substance diversion
These categories have appeared in every major health care fraud takedown in recent years, but the sustained emphasis—particularly on telemedicine and genetic testing—underscores that the DOJ views these as areas of ongoing, systemic abuse rather than isolated schemes.
Unprecedented International Cooperation and the FBI Most Wanted Fraudsters List
The DOJ described the international component of the takedown as “unprecedented.” Over the two-week enforcement period, authorities apprehended and returned to the United States:
- One defendant in Kyrenia, Cyprus, in connection with an over $3.7 billion scheme.
- Two defendants in Estonia in connection with a previously charged $10.6 billion scheme.
- In the Philippines, one of the FBI’s most wanted fraudsters in connection with a previously charged $1.2 billion telemedicine fraud scheme.
On June 4, 2026, the FBI announced the creation of its Most Wanted Fraudsters List. Among the inaugural fugitives was Herb Kimble, wanted in connection with a $1.2 billion telemedicine and durable medical equipment scheme. He was apprehended in the Philippines just four days later. The DOJ framed the takedown as demonstrating that “no fraudster can hide from the law, whether in the United States or abroad” and that the effort reflects “full-spectrum accountability for all criminal actors from doctor’s offices to corporate boardrooms.”
Multifront Exposure: Criminal, Civil, and Administrative Actions
The takedown is not limited to criminal charges. The civil component included charges against 13 defendants for $14.8 million in health care fraud schemes, plus civil settlements with 31 defendants totaling $23 million. In parallel, the DEA has initiated 928 administrative cases seeking the revocation of authority to handle and prescribe controlled substances since October 1, 2025.
This interagency coordination means a single matter can trigger parallel criminal, civil, and administrative exposure, including loss of billing privileges and payment suspension. Companies and providers must develop response strategies that account for all fronts simultaneously.
Key Takeaways for Companies and Providers
Data-driven enforcement is here to stay. Companies should expect proactive, analytics-driven scrutiny from the DOJ and CMS. Robust internal data monitoring and auditing are essential—particularly outlier analysis of billing patterns, claims volumes, and reimbursement trends. Companies must ensure they stay ahead of the government’s use of advanced analytical tools. The question is no longer whether the government will find anomalies, but when.
Emerging priority areas demand heightened compliance attention. Wound care / skin substitutes, telemedicine, genetic testing, DME, and opioid prescribing warrant close review, especially when kickbacks or medical-necessity issues may arise. Companies operating in these spaces should conduct targeted compliance assessments now.
Multifront and global exposure requires coordinated strategy. A single scheme can trigger parallel criminal, civil, and administrative actions—and, as this takedown demonstrates, cross-border enforcement. Response strategies must account for simultaneous proceedings and the interplay between them.
Patient harm raises the stakes. The DOJ’s emphasis on patient harm—including death—signals a more aggressive charging and sentencing posture. Schemes that can be characterized as causing direct physical harm to patients will face heightened scrutiny and more severe consequences.
Proactive compliance review is critical. Companies should review and strengthen compliance programs, billing practices, marketing and kickback controls, and provider/vendor due diligence. The accelerating pace of enforcement—and the DOJ’s increasingly sophisticated detection capabilities—make reactive postures untenable.
Alston & Bird’s False Claims Act and health care enforcement attorneys are closely monitoring these developments and regularly assist clients facing health care fraud scrutiny—whether criminal, civil, or administrative. Clients with questions about the 2026 National Health Care Fraud Takedown or their compliance posture should contact their Alston & Bird relationship partner or a member of the team.
If you have any questions, or would like additional information, please contact one of the attorneys on our White Collar, Government & Internal Investigations team or one of the attorneys on our Health Care Litigation team.
You can subscribe to future advisories and other Alston & Bird publications by completing our publications subscription form.